Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nipocalimab withdrawal study in adults with CIDP
2023-508425-28-00Phase 2Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 20
01
Overview
Phase 2, randomised, double-blind trial in chronic inflammatory demyelinating polyneuropathy (CIDP) comparing Nipocalimab with Placebo (2 arms). Primary endpoint: Time to first relapse event. Planned start Oct 2022; status: authorised.
02
Drugs
nipocalimab
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on 2023-508425-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508425-28-00.